MARKET

IBIO

IBIO

Ibio
NASDAQ
1.880
-0.010
-0.53%
After Hours: 1.890 +0.01 +0.53% 18:07 12/18 EST
OPEN
2.000
PREV CLOSE
1.890
HIGH
2.130
LOW
1.870
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
6.89
52 WEEK LOW
0.5562
MARKET CAP
42.28M
P/E (TTM)
-1.3077
1D
5D
1M
3M
1Y
5Y
1D
iBio initiated with an Outperform at LifeSci Capital
TipRanks · 15h ago
Analysts Conflicted on These Healthcare Names: Ibio (IBIO), Q32 Bio (QTTB) and Progyny (PGNY)
TipRanks · 16h ago
EcoR1 Capital Reports 9.9% Passive Stake In IBio As Of Dec 10
Benzinga · 1d ago
ECOR1 CAPITAL LLC REPORTS 9.9% PASSIVE STAKE IN IBIO INC AS OF DEC 10- SEC FILING
Reuters · 1d ago
Weekly Report: what happened at IBIO last week (1208-1212)?
Weekly Report · 3d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/11 16:45
3 Penny Stocks to Watch Now, 12/11/25
TipRanks · 12/11 15:55
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 12/10 17:05
More
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Webull offers Ibio Inc stock information, including NASDAQ: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.